Scorpion Sting Envenomation Clinical Trial
Official title:
Open Label, Confirmatory, Controlled Clinical Study of Alacramyn® in Pediatric Patients With Scorpion Sting Envenomation
There is no FDA approved therapy for the treatment of scorpion envenomation in the United States. Centruroides scorpion envenomation produces a pattern of neurotoxicity with a spectrum of severity ranging from trivial to life threatening. Patients stung by Centruroides scorpions develop a clinical syndrome which may require sedation with benzodiazepines and observation for 6 to 28 hours of intensive care monitoring. A safe therapy is necessary to halt the progression of symptoms early in the clinical course while avoiding the clinical deterioration that can occur en route to a tertiary facility. Alacramyn® is anticipated to be safer and more effective than the present standard of care in the United States, midazolam, and faster-acting thus eliminating the need to transport most rural patients and reducing hospitalization time.
The purpose of this open label, confirmatory, controlled clinical trial in Mexico was to
provide additional data safety and efficacy of Alacramyn® for treatment of patients
envenomed by scorpion sting.
This study took place at Morelos Children's Hospital in Cuernavaca, Mexico.
Patients who arrived at the emergency department presenting with scorpion sting symptoms
were evaluated for treatment with respect to the inclusion/exclusion criteria according to
the study procedures. Only patients with clinically important systemic signs of scorpion
sting envenomation were included in the study. Baseline measures included severity
evaluation of the scorpion sting envenomation. The patient's vital signs, concomitant
medication, medical history and demographic data were collected. Blood tests were done for
haematology, chemistry, venom and anti-venom levels and urine test.
After informed consent and inclusion/exclusion criteria were obtained and verified, and the
baseline measurements completed, three vials of Alacramyn® were administered. At the one
hour assessment an additional vial of Alacramyn® was administered if important systemic
signs of scorpion envenomation were present. The assessment was repeated at two hours and a
final vial of Alacramyn® was administered if deemed necessary. Patient were discharged after
the 4 hour assessment if symptoms were resolved. Prior to discharge repeat lab work,
physical assessments, and vital signs were done. Those remaining for extended care underwent
final study assessments at time of hospital discharge or at 24 hours after study drug
infusion if hospitalization continued.
All patients who participated in the study were contacted 7 and 14 days after treatment,
looking for symptoms suggestive of ongoing venom effect, delayed serum sickness, as well as
for any other adverse event reported by the patient.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00624078 -
Treatment Protocol for Use of Anascorp™ in Patients With Scorpion Sting Envenomation
|
Phase 2/Phase 3 | |
| Completed |
NCT00685230 -
Double-Blind, Alacramyn® vs. Placebo in Pediatric Patients
|
Phase 2/Phase 3 | |
| Completed |
NCT00696683 -
Establishment of Natural History of Scorpion Envenomation
|
N/A | |
| Completed |
NCT01599936 -
Open Label Clinical Trial of Alacramyn® in Pediatric Patients With Scorpion Sting Envenomation
|
Phase 3 |